Operator
Good afternoon, ladies and gentlemen. Thank you for joining Dropbox first-quarter 2021 earnings conference call. [Operator instructions] As a reminder, this conference call is being recorded and will be available for replay from the Investor Relations section of Dropbox s website following this call. I will now turn it over to Page Portas, investor relations at Dropbox.
Ms. Portas, please go ahead.
Page Portas
Investor Relations
Today, Dropbox will discuss quarterly financial results that were distributed earlier. Statements on this call include forward-looking statements, including future financial results, including our goals and expectations regarding future revenue growth, profitability and our ability to generate and sustain positive free cash flow, our expectations regarding anticipated impact to our financial results, including estimated impairment charges and subleasing income as a result of our shift to a virtual-first work model, expected performance of our
Pa Schools React to Restriction Changes 11:14 pm
With Governor Tom Wolf’s announcement of eased restrictions going into effect on Memorial Day, how will this effect schools in Cambria County?
Although Gov. Wolf’s administration announced the lifting of COVID-19 restrictions beginning May 31, not every school district will see a significant change this year. It will depend on when the district’s graduation dates are set.
Westmont Hilltop High School seniors will be graduating on the evening of May 26, just a handful of days before Gov. Tom Wolf’s COVID-19 restrictions are set to be lifted.
“So, we will be following the old orders which limits us to 25% capacity and 50% in outdoor capacity,” said Westmont Hilltop’s superintendent, Thomas Mitchell.
(1)
DEFINING CLEAR DEVELOPMENT PATHWAY FOR NEXT GENERATION OF PSYCHEDELIC MEDICINES TO TREAT ADDICTION
Toronto, Ontario (Newsfile Corp. - April 27, 2021) - Awakn Life Sciences Inc. (Awakn), a biotechnology company with clinical operations researching, developing, and delivering psychedelic medicines to treat Addiction, announced today the initiation of a new chemical entity (NCE) development program to strengthen Awakn s pipeline for the treatment of a broad range of addictions. The Company has also announced the appointment of Evotec as NCE research partner and the selection of Prof. David Nutt, one of the world s leading experts on addiction, as program lead.
This announcement follows Awakn s March 2021 acquisition of a significant body of proprietary research from Equasy Enterprises, including details of newly discovered actions of MDMA (Equasy Acquisition).
DEFINING CLEAR DEVELOPMENT PATHWAY FOR NEXT GENERATION OF PSYCHEDELIC MEDICINES TO TREAT ADDICTION Awakn Life Sciences Inc. (Awakn), a biotechnology company with clinical operations researching, developing, and delivering psychedelic medicines to treat Addiction, announced today the initiation of a new chemical entity (NCE) development program to strengthen Awakn’s pipeline for the treatment of a broad … Continued
DEFINING CLEAR DEVELOPMENT PATHWAY FOR NEXT GENERATION OF PSYCHEDELIC MEDICINES TO TREAT ADDICTION
Awakn Life Sciences Inc. (Awakn), a biotechnology company with clinical operations researching, developing, and delivering psychedelic medicines to treat Addiction, announced today the initiation of a new chemical entity (NCE) development program to strengthen Awakn’s pipeline for the treatment of a broad range of addictions. The Company has also announced the appointment of Evotec as NCE research partner and the selection of Prof. David Nutt, one of the world’s lead
PsyBio and Miami University Broaden Partnership Agreement for the Continued Advancement of its Neuropsychiatric Drug Discovery Platform, Expediting its IND Submission to the FDA
News provided by
Share this article
Share this article
PsyBio or the
Company ), a biotechnology company pioneering the next generation of targeted psychoactive medications, announces today that it has amended its master sponsored agreement with Miami University based in Oxford, Ohio (the
Amended Agreement ) to extend and expand the research efforts of the laboratory of Dr. J. Andrew Jones in the Department of Chemical, Paper, and Biomedical Engineering (the
Jones Lab ), to include additional research efforts of the laboratory of Dr. Matthew McMurray in the Department of Psychology (the